Redx Pharma (LSE:REDX) EV-to-EBIT : -1.87 (As of May. 21, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Redx Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Redx Pharma's Enterprise Value is £57.94 Mil. Redx Pharma's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was £-30.99 Mil. Therefore, Redx Pharma's EV-to-EBIT for today is -1.87.

The historical rank and industry rank for Redx Pharma's EV-to-EBIT or its related term are showing as below:

LSE:REDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -20.1 Med: -3.92 Max: 6.35
Current: -1.87

During the past 12 years, the highest EV-to-EBIT of Redx Pharma was 6.35. The lowest was -20.10. And the median was -3.92.

LSE:REDX's EV-to-EBIT is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 10.09 vs LSE:REDX: -1.87

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Redx Pharma's Enterprise Value for the quarter that ended in Sep. 2023 was £86.67 Mil. Redx Pharma's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was £-30.99 Mil. Redx Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -35.75%.

Redx Pharma EV-to-EBIT Historical Data

The historical data trend for Redx Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redx Pharma EV-to-EBIT Chart

Redx Pharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EV-to-EBIT

Get a 7-Day Free Trial

-1.77

-12.60

-11.31

-9.56

-2.80

Redx Pharma Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial															-11.31	-	-9.56	-	-2.80

Competitive Comparison of Redx Pharma's EV-to-EBIT

For the Biotechnology subindustry, Redx Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Redx Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Redx Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Redx Pharma's EV-to-EBIT falls into.

Redx Pharma EV-to-EBIT Calculation

Redx Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	57.937	/	-30.987
	=	-1.87

Redx Pharma's current Enterprise Value is £57.94 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Redx Pharma's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was £-30.99 Mil.

Redx Pharma (LSE:REDX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Redx Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	-30.987	/	86.66586
	=	-35.75 %

Redx Pharma's Enterprise Value for the quarter that ended in Sep. 2023 was £86.67 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Redx Pharma's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was £-30.99 Mil.

Redx Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Redx Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Redx Pharma (LSE:REDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redx Pharma PLC (LSE:REDX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Block 33, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG

Website

https://www.redxpharma.com

Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.

Redx Pharma (LSE:REDX) Headlines

No Headlines